Work

Rapid development of drug resistance during initial dolutegravir-based antiretroviral therapy of an infant with HIV

Year: 2025

Type: article

Abstract: Dolutegravir resistance is predominantly reported in antiretroviral therapy-experienced individuals. We describe an infant who developed high-level resistance to abacavir, lamivudine, and dolutegravir within 97 days of initiation, despite initial wild-type infection. Causative factors likely include probable sub-therapeutic antiretroviral drug levels, poor tolerance, severe immunocompromise, and a high pre-treatment viral load. What this study adds: The evolution of DTG resistance from a confirmed transmitted wild-type virus in this infant is more rapid than previously described. Identification of risk factors for developing DTG resistance in infants requires further investigation.

Source: Southern African Journal of HIV Medicine

DOI: 10.4102/sajhivmed.v26i1.1750

Authors: Natasha L. O'Connell, Tara-Lee von Mollendorff, Gert van Zyl, Stephen Korsman, James Nuttall

Institutions: University of Cape Town, Stellenbosch University, National Health Laboratory Service, Groote Schuur Hospital

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $605